0001209191-22-014173.txt : 20220301 0001209191-22-014173.hdr.sgml : 20220301 20220301171936 ACCESSION NUMBER: 0001209191-22-014173 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220225 FILED AS OF DATE: 20220301 DATE AS OF CHANGE: 20220301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ramelmeier Rolf Andrew CENTRAL INDEX KEY: 0001789340 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 22699752 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-02-25 0 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001789340 Ramelmeier Rolf Andrew C/O SANGAMO THERAPEUTICS, INC. 7000 MARINA BLVD. BRISBANE CA 94005 0 1 0 0 EVP, Technical Operations Common Stock 2022-02-25 4 F 0 12388 5.90 D 88429 D Common Stock 2022-02-25 4 A 0 54000 0.00 A 142429 D Stock Option (Right to Buy) 5.90 2022-02-25 4 A 0 145800 0.00 A 2032-02-24 Common Stock 145800 145800 D Represents shares underlying the portions of restricted stock unit ("RSU") grants that vested on February 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on February 25, 2022 of $5.90/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). Includes: (a) 2,727 shares resulting from the February 25, 2022 final vesting installment of the Reporting Person's February 25, 2019 RSU grant, (b) 11,993 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2020 RSU grant and 18,337 shares subject to such RSU grant that will vest in one final annual installment on February 25, 2023, and (c) 8,722 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2021 RSU grant and 26,668 shares subject to such RSU grant that will vest in two remaining annual installments of 13,332 shares and 13,336 shares on February 25, 2023 and 2024, respectively. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Includes 2,000 shares acquired on April 30, 2021 and 346 shares acquired on October 29, 2021 under the Issuer's 2010 Employee Stock Purchase Plan and 272 shares acquired on May 8, 2021 under the Issuer's 2020 Employee Stock Purchase Plan. Represents shares of common stock issuable upon settlement of an RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Rolf Andrew Ramelmeier, by /s/ Ron A. Metzger, Attorney-in-Fact 2022-03-01